Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 26, 2023
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
[ Thu, Jan 26th 2023
] - WOPRAI
Corinne Jenkins Maintained (BTAI) at Hold with Increased Target to $26 on, Jan 26th, 2023
Corinne Jenkins of Goldman Sachs, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Hold with Increased Target from $16 to $26 on, Jan 26th, 2023.
Corinne has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 0 agree with Corinne's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Corinne
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $73 on, Tuesday, January 3rd, 2023
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $18 on, Wednesday, November 16th, 2022
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022
